Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603882'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5 Med: 15.93 Max: 51.91
Current: -1.58
During the past 13 years, Guangzhou Kingmed Diagnostics Group Co's highest Return-on-Tangible-Equity was 51.91%. The lowest was -5.00%. And the median was 15.93%.
SHSE:603882's Return-on-Tangible-Equity is ranked worse than 52.6% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs SHSE:603882: -1.58
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Guangzhou Kingmed Diagnostics Group Co Return-on-Tangible-Equity Related Terms
Guangzhou Kingmed Diagnostics Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co Return-on-Tangible-Equity Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
SHSE:603882 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.71% mean?
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a Return-on-Tangible-Equity of 2.71% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. This is 83% below median its historical median of 15.93. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #101 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Guangzhou Kingmed Diagnostics Group Co's Return-on-Tangible-Equity too high?
Guangzhou Kingmed Diagnostics Group Co's current Return-on-Tangible-Equity of 2.71% is 83% below median its 10-year median of 15.93. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #101 out of 192 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #101 out of 192 companies for Return-on-Tangible-Equity. This places Guangzhou Kingmed Diagnostics Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current Return-on-Tangible-Equity is 2.71%, which is 83% below median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.02, compared to a current price of ¥25.97 — trading 7.3% below its estimated fair value. The current Return-on-Tangible-Equity is 2.71%, which is 83% below median its 10-year median of 15.93. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current Return-on-Tangible-Equity is 2.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be undervalued.
The current stock price of ¥25.97 is trading 7.3% below its estimated GF Value™ of ¥28.02.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
Return-on-Tangible-Equity: 2.71% (83% below median its 10-year median of 15.93)
GF Value™: ¥28.02 vs. price of ¥25.97 (7.3% below fair value)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Kingmed Diagnostics Group Co Business Description
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
74GF Score
Get the complete analysis for SHSE:603882
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
